local_hospital

Uniwersyteckie Centrum Stomatologii I Medycyny Specjalistycznej Sp. z o.o.

Address
lock Available on a paid plan

Cardiovascular Research

At Uniwersyteckie Centrum Stomatologii I Medycyny Specjalistycznej Sp. z o.o. in Poznan, cardiology research focuses on cardiovascular diseases, especially atherosclerotic cardiovascular disease and elevated lipoprotein(a). These studies are designed to evaluate whether new treatments can lower major heart-related risks and improve long-term outcomes.

  • Cardiovascular disease and elevated lipoprotein(a)
  • Preventing coronary heart disease events and related complications
  • Testing therapies that may reduce heart attack and revascularization risk

This area reflects a strong interest in improving prevention and treatment strategies for people at high cardiovascular risk.

Kidney and Metabolic Disease Studies

The site also supports research in nutritional and metabolic diseases and metabolism, with a major emphasis on chronic kidney disease, high proteinuria, obesity, and metabolic dysfunction-associated steatotic liver disease. The trials are mainly aimed at slowing disease progression, protecting kidney function, and improving overall metabolic health.

  • Chronic kidney disease with hypertension or high proteinuria
  • Obesity and overweight linked to metabolic disease
  • Metabolic dysfunction-associated steatotic liver disease

These studies explore whether newer treatment combinations can better preserve kidney function and support broader cardiometabolic care.

Gastroenterology and Immune-Mediated Disease Research

A substantial part of the research portfolio covers digestive system diseases and immune system diseases, especially Crohn’s disease and ulcerative colitis. The trials are focused on improving symptom control, achieving remission, and strengthening long-term disease management for patients with inflammatory bowel disease.

  • Crohn’s disease, including moderately to severely active forms
  • Ulcerative colitis and treatment maintenance
  • Evaluating combinations and newer therapies for better clinical outcomes

This research area highlights efforts to refine treatment effectiveness while also addressing quality of life in chronic intestinal inflammation.

Endocrine and Autoimmune Disorders

The site participates in studies of hormonal diseases and related autoimmune conditions, including Graves’ disease, thyroid eye disease, and classic congenital adrenal hyperplasia. These trials are designed to assess whether emerging therapies can better control hormone imbalance, reduce disease activity, and support more stable long-term management.

  • Thyroid eye disease and eye-related autoimmune inflammation
  • Graves’ disease and maintenance of normal thyroid function
  • Congenital adrenal hyperplasia and adrenal hormone control

This therapeutic area combines endocrine care with autoimmune research, reflecting a broad effort to improve outcomes in complex hormone-related disorders.

Diabetes and Broader Metabolic Care

Research at this hospital/clinic also includes type 1 diabetes and related metabolic conditions. The main goal is to evaluate treatment options that may improve glycaemic control and make diabetes management more effective and practical for patients living with long-term metabolic disease.

  • Type 1 diabetes and blood sugar control
  • Supporting better day-to-day metabolic management
  • Comparing new approaches with established insulin-based care

These studies add to the site’s wider focus on metabolism and chronic disease care.

Site Overview

assignment
23
connected trials
corporate_fare
9
sponsors
science
20
IMPs

Activity Indicator

Last 6 months

7
Trials started
+40% vs previous period.
5
Trials started 6–12 months ago
23
Total trials linked
Highly Active
trending_upGrowing+40%
1
2
2
2
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 5 of 9 therapeutic areas and 15 of 20 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years
lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
15
Sponsors (total)
9
Active sponsors
7

Sponsor Network

Top 7 by active trials.

lock +6 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +5 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 1 624 other sites in Poland

description
Trial volume
23
Outperforms 88% of sites
public
Therapeutic diversity
9areas
Outperforms 93% of sites
groups
Sponsor diversity
9sponsors
Outperforms 80% of sites

Therapeutic Area Benchmark — Poland

Select a therapeutic area to compare against other sites in Poland.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Poland

Market Share

Country: Poland

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Uniwersyteckie Centrum Stomatologii I Medycyny Specjalistycznej Sp. z o.o.

lock Showing 1 of 23 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol to Evaluate the Efficacy and Safety of Icotrokinra in Participants With Moderately to Severely Active Crohn's DiseaseJanssen Cilag InternationalPhase IVRecruitingDec 2025

IMP list

lock Showing 1 of 20 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Azd50044Unknown

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.